Overall Score

Business Model Market Opportunity

Micro-cap biotech with no revenue and no demonstrated commercial scale.

Long-term upside depends on successful clinical development and eventual monetization, which remains highly uncertain.

Financial Health Cash Runway

Current ratio is 1.97 and cash per share is 2.25, indicating near-term liquidity is not immediately strained.

Enterprise value is negative and working capital is positive, but the company still shows negative free cash flow and weak solvency metrics.

Growth Trajectory Reinvestment

No revenue base or operating growth is visible in the TTM data.

Negative operating cash flow and free cash flow suggest the business is still consuming capital rather than reinvesting from internally generated growth.

Profitability Efficiency

Margins are effectively zero and returns on assets, equity, and invested capital are all deeply negative.

Income quality is weak, reinforcing that current operations are not producing durable earnings power.

Valuation Shareholder Returns

Traditional valuation multiples are not meaningful with no revenue and negative earnings.

Book value support exists, but there is no dividend and no evidence of shareholder return generation.